Indication

TOCIT-5 Tablet is prescribed for treating various inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis.

Pharmacology

TOCIT-5 Tablet comprises tocilizumab, a humanized monoclonal antibody designed to bind to the interleukin-6 (IL-6) receptor, thereby inhibiting IL-6 signaling. IL-6 is a cytokine that plays a pivotal role in regulating immune responses and inflammation. By obstructing IL-6 signaling, tocilizumab mitigates inflammation and alleviates symptoms associated with inflammatory conditions.

Dosage and Administration

The recommended dose of TOCIT-5 Tablet varies based on the specific condition being treated and the patient’s response to treatment. Typically, it is administered either through intravenous infusion or subcutaneous injection. The dosage regimen may differ, necessitating adherence to healthcare provider instructions or product labeling.

Interaction

TOCIT-5 Tablet may interact with other medications, especially those influencing the immune system or increasing infection risk. Concurrent use of tocilizumab with immunosuppressive agents or live vaccines can heighten immunosuppression and the likelihood of infections. Therefore, consulting a healthcare professional before starting or discontinuing any medication alongside TOCIT-5 Tablet is imperative.

Side Effects

Common adverse effects linked to TOCIT-5 Tablet encompass upper respiratory tract infections, nasopharyngitis, headaches, hypertension, elevated liver enzymes, and infusion-related reactions. Serious adverse reactions may include severe infections, gastrointestinal perforation, hepatotoxicity, and hypersensitivity reactions.

Precautions and Warnings

TOCIT-5 Tablet should be approached cautiously in patients with a history of infections, pre-existing gastrointestinal disorders, hepatic impairment, or hypersensitivity to tocilizumab or its constituents. Vigilant monitoring for infection signs, liver function abnormalities, and infusion-related reactions is advised during TOCIT-5 Tablet therapy.

Overdose Effects

In cases of TOCIT-5 Tablet overdose, supportive care and symptomatic treatment should be initiated promptly. Limited information is available regarding tocilizumab overdose, necessitating management based on clinical judgment and patient condition. Vigilant monitoring for adverse reactions and complications is crucial in instances of tocilizumab overdose.